NASDAQ:RNXT RenovoRx (RNXT) Stock Price, News & Analysis $1.19 -0.06 (-4.80%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$1.26 +0.07 (+5.88%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About RenovoRx Stock (NASDAQ:RNXT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RenovoRx alerts:Sign Up Key Stats Today's Range$1.16▼$1.2650-Day Range$0.87▼$1.4052-Week Range$0.75▼$1.69Volume683,462 shsAverage Volume359,946 shsMarket Capitalization$43.61 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingBuy Company Overview RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Read More RenovoRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreRNXT MarketRank™: RenovoRx scored higher than 44% of companies evaluated by MarketBeat, and ranked 718th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRenovoRx has only been the subject of 1 research reports in the past 90 days.Read more about RenovoRx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RenovoRx is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RenovoRx is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenovoRx has a P/B Ratio of 6.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about RenovoRx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.38% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently increased by 54.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRenovoRx does not currently pay a dividend.Dividend GrowthRenovoRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.38% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently increased by 54.84%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News SentimentN/A News SentimentRenovoRx has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for RenovoRx this week, compared to 1 article on an average week.Search Interest5 people have searched for RNXT on MarketBeat in the last 30 days. MarketBeat Follows3 people have added RenovoRx to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $38,700.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.13% of the stock of RenovoRx is held by insiders.Percentage Held by InstitutionsOnly 3.10% of the stock of RenovoRx is held by institutions.Read more about RenovoRx's insider trading history. Receive RNXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNXT Stock News HeadlinesDiscovering the Next Wave of Biotech Innovation (MDCX, RNXT, JSPR, LSB)August 22, 2025 | theglobeandmail.comRenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025August 20, 2025 | finance.yahoo.comNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do… | Brownstone Research (Ad)RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025August 20, 2025 | businesswire.comRenovoRx, Inc. (NASDAQ:RNXT) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | msn.comRenovoRx Revenue Jumps 28 Percent in Q2August 14, 2025 | theglobeandmail.comRenovoRx Reports Strong Q2 2025 Revenue GrowthAugust 14, 2025 | msn.comRenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data ReviewAugust 14, 2025 | businesswire.comSee More Headlines RNXT Stock Analysis - Frequently Asked Questions How have RNXT shares performed this year? RenovoRx's stock was trading at $1.29 at the start of the year. Since then, RNXT shares have decreased by 7.8% and is now trading at $1.19. How were RenovoRx's earnings last quarter? RenovoRx, Inc. (NASDAQ:RNXT) released its earnings results on Thursday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.42 million for the quarter, compared to the consensus estimate of $0.25 million. Read the conference call transcript. When did RenovoRx IPO? RenovoRx (RNXT) raised $18 million in an initial public offering (IPO) on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO. Who are RenovoRx's major shareholders? RenovoRx's top institutional shareholders include AWM Investment Company Inc. (5.11%), Geode Capital Management LLC (0.97%), Corsair Capital Management L.P. (0.26%) and Northwestern Mutual Wealth Management Co. (0.20%). Insiders that own company stock include Ramtin Agah, Shaun Bagai, Laurence Marton, Ron Kocak and Angela Nelms. View institutional ownership trends. How do I buy shares of RenovoRx? Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RenovoRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN). Company Calendar Last Earnings8/14/2025Today9/04/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNXT CIK1574094 Webwww.renovorx.com Phone650-284-4433Fax650-397-4433Employees6Year FoundedN/APrice Target and Rating Average Price Target for RenovoRx$7.50 High Price Target$12.00 Low Price Target$3.00 Potential Upside/Downside+530.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.81 million Net MarginsN/A Pretax Margin-1,610.88% Return on Equity-120.68% Return on Assets-89.23% Debt Debt-to-Equity RatioN/A Current Ratio8.61 Quick Ratio8.61 Sales & Book Value Annual Sales$40 thousand Price / Sales1,090.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book6.26Miscellaneous Outstanding Shares36,650,000Free Float33,300,000Market Cap$43.61 million OptionableNot Optionable Beta1.24 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RNXT) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.